Key points are not available for this paper at this time.
Among patients with node-positive tumors, ER-negative breast cancer, biweekly doxorubicin/cyclophosphamide plus paclitaxel lowers the rate of recurrence and death by more than 50% in comparison with low-dose cyclophosphamide, doxorubicin, and fluorouracil as used in the first study.
Building similarity graph...
Analyzing shared references across papers
Loading...
Berry et al. (Tue,) studied this question.
www.synapsesocial.com/papers/69d8e8a62c39562886ae3261 — DOI: https://doi.org/10.1001/jama.295.14.1658
Donald A. Berry
Constance Cirrincione
I. Craig Henderson
JAMA
University of California, San Francisco
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Building similarity graph...
Analyzing shared references across papers
Loading...